Based on these observations, the authors speculated that thyroid cancer patients with low tumor levels of β-TRCP (resulting in high levels of VEGFR2) may respond more favorably to treatment with sorafenib, and perhaps other tyrosine kinase inhibitors as well. Here, BTRC is linked to thyroid cancer.